Loading resource…

Amsterdam UMC, University of Pisa, McMaster University
Over the past two decades, there has been a significant transition from vitamin K antagonists to direct oral anticoagulants (DOACs), which include agents like dabigatran and factor Xa inhibitors such as apixaban, edoxaban, and rivaroxaban. Despite their advantages, DOACs can still lead to bleeding, especially in vulnerable populations. The document reviews existing and emerging reversal agents, including ciraparantag, and highlights the need for further research to establish optimal strategies for managing bleeding in patients on these anticoagulants.
No account needed